Supernus Pharmaceuticals. has filed a patent for modified release formulations of viloxazine, with high-drug load formulations. The formulation includes extended and delayed release components, with specific coatings and excipients. The patent aims to provide an effective method of administering viloxazine. GlobalData’s report on Supernus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Supernus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Supernus Pharmaceuticals's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Modified release formulation of viloxazine with high-drug load
A modified release formulation of viloxazine has been claimed in a filed patent (Publication Number: US20230381191A1). The formulation includes viloxazine as the sole active pharmaceutical ingredient and comprises either an extended release component or a delayed release component. The extended release component consists of a core with viloxazine, a coating of a release rate controlling compound, and pharmaceutically acceptable excipients. The delayed release component includes a core with viloxazine and a coating of an enteric compound with pH-dependent solubility. The release rate controlling compound can be hydrophilic or hydrophobic, with specific compounds listed in the claim. The formulation ranges from 5% to 65% of the release rate controlling compound, 5% to 50% of the enteric compound, and 25% to 75% of viloxazine.
Furthermore, the patent claim details the method of treating a CNS disorder in a mammalian subject by administering the formulated viloxazine. The CNS disorders mentioned include ADHD, ADHD related disorders, and major depressive disorder. The administration can be once or twice a day, resulting in a reduced level of undesirable side effects compared to immediate release formulations. Undesirable side effects such as gastrointestinal issues and neurological disturbances like sleep disturbances are specifically addressed. The formulation can be administered to both human children and adults, with a daily dose ranging from 10 mg to 800 mg and viloxazine content from 25% to 75%. Additionally, the formulation can be in various dosage forms like tablets, capsules, or suspensions, and can also be a gastro-retentive formulation.
To know more about GlobalData’s detailed insights on Supernus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
